Quetiapine
Quetiapine
Quetiapine
Generic Name quetiapine Peak unknown Trade Name Seroquel Onset unknown Classification Antipsychotic Duration 8-12 hrs Dose Route Time/frequency 2 tab 25 mg PO Q am 50 mg total PO 830 Normal dosage range 100 mg/day in two divided doses on day 1, increase dose by 100 mg/day up to 400 mg/day by day 4, then may increase in 200 mg/day increments up to 800 mg/day on day 6 if required. For IV meds, compatibility with IV drips and/or solutions N/A Nursing Implications (what to focus on) Contraindications/warnings/interactions Hypersensitivity. Cardiovascular disease, cerebrovascular disease, dehydration or hypovolemia (increased risk of hypotension). History of seizures, Alzheimers type dementia. Geriatric patients (may require doses; inappropriate use for dementia is associated with mortality), hepatic impairment (dosage reduction may be necessary), hypothyroidism (may be exacerbated). Common side effects NEUROLEPTIC MALIGNANT SYNDROME, SEIZURES, dizziness, weight-gain Lab value alterations caused by medicine May cause asymptomatic in AST and ALT. May also cause anemia, thrombocytopenia, leukocytosis, and leucopenia.
Why is your patient getting this medication Bipolar mania Mechanism of action and indications (Why med ordered) Probably acts by serving as an antagonist of dopamine and serotonin. Also antagonizes histamine H1 receptors and alpha1adrenergic receptors.
Interactions with other patient drugs, OTC or herbal medicines (ask patient specifically) Lantus: The efficacy of oral hypoglycemic agents and insulin may be diminished by certain drugs, including thiazides and other diuretics, corticosteroids, estrogens, progestins, thyroid hormones, human growth hormone, phenothiazines, atypical antipsychotics, sympathomimetic amines, protease inhibitors, phenytoin, clozapine, megestrol, danazol, isoniazid, asparaginase, pegaspargase, diazoxide, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. Nitroglycerin: Neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy. Proventil, Levaquine: There is some concern that quetiapine may have additive adverse cardiovascular effects in combination with other drugs that are known to prolong the QT interval of the electrocardiogram. Data are conflicting. In clinical trials, there was no statistically significant difference between quetiapine and placebo in the proportions of patients experiencing potentially important changes in ECG parameters including QT, QTc, and PR intervals. However, QT prolongation has been reported in quetiapine overdose and with therapeutic use of other atypical antipsychotic agents such as sertindole, ziprasidone, and risperidone. In one case report, torsade de pointes arrhythmia developed in a patient treated with low-dose quetiapine. However, the relationship to quetiapine is uncertain, as there were multiple confounding risk
Seroquel (quetiapine)
factors such as hypomagnesemia, a history of QT prolongation (possibly prior to initiation of quetiapine), a history of substance abuse, and uncertain medication compliance. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). Coreg, Demadex: Neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy. Gabapentin: Central nervous system- and/or respiratorydepressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients. Reglan: Coadministration of metoclopramide with phenothiazines or other neuroleptic agents may increase the risk of severe extrapyramidal reactions. The mechanism is additive antidopaminergic effects. In addition, central nervous system-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients. Grapefruit juice: Grapefruit juice may increase the plasma concentrations of some orally administered drugs that are substrates of the CYP450 3A4 isoenzyme. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. The extent and clinical significance are unknown. Moreover, pharmacokinetic alterations associated with interactions involving grapefruit juice are often subject to a high degree of interpatient variability. Nursing Process- Assessment Assessment (Pre-administration assessment) Why would you hold or not give this med? Monitor mental status (mood, ideation, delusions, Monitor for development of neuroleptic hallucinations, behavior) before and periodically malignant syndrome (fever, respiratory during therapy. Monitor mood changes. Assess distress, tachycardia, seizures, diaphoresis, for suicidal tendencies, especially during early hypertension or hypotension, pallor, therapy. Restrict amount of drug available to tiredness). Notify physician or other health patient. Monitor blood pressure (sitting, standing, care professional immediately if these lying) and pulse before and frequently during symptoms occur. Hypersensitivity. Seizure. initial dose titration. If hypotension occurs during dose titration, return to the previous dose. Observe patient carefully when administering to ensure medication is swallowed and not hoarded. Monitor for onset of extrapyramidal side effects (akathisia--restlessness;dystonia--muscle spasms and twisting motions; or pseudoparkinsonism-mask-like faces, rigidity, tremors, drooling, shuffling gait, dysphagia). Report these symptoms;
Evaluation Check after giving Decrease in excited, manic, paranoiac or withdrawn behavior. Make sure patient has swallowed medication and is not cheeking or holding meds.
Seroquel (quetiapine)
reduction of dose or discontinuation may be necessary. Trihexyphenidyl or diphenhydramine may be used to control these symptoms. Monitor for tardive dyskinesia (involuntary rhythmic movement of mouth, face, and extremities). Report immediately; may be irreversible.
Seroquel (quetiapine)